DOJ announced a $30 million resolution involving Advanced Pathology Solutions (APS) and current/former owners. The government alleged unlawful kickbacks and medically unnecessary testing tied to federal healthcare programs.

The U.S. Department of Justice announced that Advanced Pathology Solutions (APS) and current and former owners agreed to pay $30 million to resolve allegations involving kickbacks and medically unnecessary testing. DOJ’s announcement framed the matter as healthcare fraud conduct that can harm patients and inflate costs within taxpayer-funded and federal healthcare program systems. Kickback schemes in healthcare often involve compensation tied to patient referrals, test ordering, or contracting decisions. DOJ alleged that APS furnished unlawful kickbacks, meaning payments or benefits were allegedly used to induce referrals or ordering practices that the government contends were improper under healthcare fraud laws. Alongside the kickback allegations, DOJ also asserted that APS ordered medically unnecessary testing—conduct that can increase billing amounts without legitimate clinical need. Settlements of this type typically aim to resolve alleged violations while allowing enforcement agencies to deter similar conduct by other providers. Even when the resolution is civil or settlement-based (as opposed to a criminal conviction), it can trigger follow-up scrutiny from compliance teams, insurers, and regulators. It may also lead to ongoing internal audits and stricter controls for ordering and billing, including documentation to support medical necessity. For patients and consumers, the case underscores that “more testing” is not automatically better. If testing is ordered without a clear medical basis, it can reflect fraud-driven incentives rather than patient care. The DOJ resolution signals that agencies continue to focus on both the referral incentive mechanisms and the clinical appropriateness of ordered services.